XTALPI Achieves First-Ever Semi-Annual Profit, Driven by Breakthrough Drug Discovery Collaborations and AI-Robotics Platform Expansion

Aug 28, 2025 18:03 CST Updated 18:03

XtalPi

Computation-Driven Innovative Drug R&D Provider

On the evening of August 27, XtalPi released its financial results announcement for the six months ended June 30, 2025.

The financial report shows that XtalPiFirst Half of the YearRevenue517 million yuan, a year-on-year increase of 403.8%.

It is worth mentioning that,XtalPi Achieves First Half-Year Profit Since Going Public, the first half of the yearAdjusted Net ProfitFor142 million yuan。

In addition, the company's cash balance amounts to RMB 5.307 billion, with a healthy cash flow situation.

In terms of revenue, XtalPiRevenue from drug discovery solutions business achieved very strong growth, with revenue from this segment in the first half of the year reachingRMB 435.2 million, compared with the same period last yearIncreased by 615.2%.

This growth mainly stems from DoveTree MedicinesThe huge cooperation.

In August this year, XtalPi announced the signing of a pipeline cooperation agreement with DoveTree Medicines, with a total order value of approximately HKD 47 billion (USD 5.99 billion), and has received the first payment of approximately HKD 400 million (USD 51 million) as stipulated in the agreement.

Besides,XtalPi and Pfizer Further Expanded Strategic Cooperation at the End of June to Jointly Develop a New Generation of Molecular Simulation Platform, Aiming to Integrate Advanced Physical Algorithms with AI Models to Improve Drug R&D Efficiency and Accelerate the Discovery and Development of Small Molecule Drugs.

Similarly,Intelligent Robot SolutionsBusiness revenue achieved rapid growth. As of June 30, 2024, this portion of revenue was81.9 million yuan, compared to the same period last yearIncreased by 95.9%.

This business is mainly for XtalPi"AI + Robotics + Automated Laboratory Platform"，Except forPromote Drug R&D ParadigmTheChange, still supporting its progress towardsExpansion into diversified fields such as materials, new energy, cosmetics, and health products。

In terms of expenditure, XtalPiR&D expenses increased from RMB 210 million in the same period of 2024 to RMB 222 million.An increase of 5.3%

。

General and administrative expenses decreased from 234 million yuan to 200 million yuan.

，

A decrease of 14.5%

, the company said, this part

Mainly due to the absence of listing expenses and a reduction in share-based compensation expenses.

The transition from loss to profit marks that XtalPi's years of investment in high value-added fields such as AI pharmaceuticals and new materials has started to pay off, serving as a benchmark in the industry.

—The End—

Recommended Reading